Programmed Cell Death 1 Ligand 2 Archives | MSD Oncology Clinical Trials

Coformulation of Pembrolizumab/Vibostolimab Versus Pembrolizumab Monotherapy for Programmed Cell Death 1 Ligand 1 Positive Metastatic Non-Small Cell Lung Cancer

March 7, 2022

The primary hypotheses are that coformulated pembrolizumab/vibostolimab is superior to pembrolizumab alone with respect to (1) overall survival (OS) in participants with programmed cell death 1 ligand 1 (PD-L1) tumor proportion

Study of Pembrolizumab in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent

March 7, 2022

By Tyler Kalist

The purpose of this study is to compare pembrolizumab + adjuvant chemotherapy with placebo + adjuvant chemotherapy, with or without radiotherapy, with respect to disease-free survival (DFS) as assessed radiographically by

Study Keyword: Programmed Cell Death 1 Ligand 2

Study Keyword: Programmed Cell Death 1 Ligand 2

Coformulation of Pembrolizumab/Vibostolimab Versus Pembrolizumab Monotherapy for Programmed Cell Death 1 Ligand 1 Positive Metastatic Non-Small Cell Lung Cancer

Study of Pembrolizumab in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent